Company: SCLXW
Filing Date: 2025-01-17
Form Type: 10-Q
Source: 0000950170-25-006755
Chunk: 45

Company: Scilex Holding Co
Filing Date: 2025-01-17
Form: 10-Q
Item: Item 1
Chunk 45
---
 cash equivalents and restricted cash at end of period
    $
    8,116

    $
    1,980

    Supplemental disclosure:

    Non-cash investing and financing activities

    Issuance of shares to B. Riley pursuant to B. Riley Purchase Agreement
    $
    —

    $
    1,869

    Issuance costs related to Bought Deal Offering and Registered Direct Offering included in accrued expenses and account payables
    $
    1,430

    $
    —

    Conversion of Convertible Debentures into common stock
    $
    —

    $
    7,735

    Right-of-use assets obtained in exchange for operating lease liabilities with lease modification
    $
    —

    $
    2,523

    Oramed Note issuance at fair value
    $
    —

    $
    106,252

    Other non-cash consideration in connection with share repurchase
    $
    —

    $
    26,154

    Excise tax in connection with share repurchase included in accrued expenses
    $
    —

    $
    1,375

See accompanying notes to unaudited condensed consolidated financial statements

 5

SCILEX HOLDING COMPANY 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Nature of Operations and Basis of Presentation Organization and Principal Activities Scilex Holding Company (“Scilex” and together with its wholly owned subsidiaries, the “Company”) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has five wholly owned subsidiaries: Scilex Inc. (“Legacy Scilex”), Scilex Pharmaceuticals Inc. (“Scilex Pharma”), Semnur Pharmaceuticals, Inc. (“Semnur”), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC. The business combination with Vickers (the “Business Combination”) closed in November 2022. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (“ZTlido”), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. In June 2022, the